Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gastroenterology | 9 | 2025 | 33 | 2.890 |
Why?
|
| Gastrointestinal Diseases | 8 | 2021 | 125 | 1.820 |
Why?
|
| Artificial Intelligence | 2 | 2025 | 116 | 1.610 |
Why?
|
| Pediatrics | 3 | 2025 | 295 | 1.570 |
Why?
|
| Abdominal Pain | 6 | 2022 | 85 | 1.570 |
Why?
|
| Urinary Tract Infections | 4 | 2018 | 57 | 1.560 |
Why?
|
| Vomiting | 3 | 2025 | 73 | 1.190 |
Why?
|
| Receptors, CCR2 | 2 | 2018 | 13 | 1.020 |
Why?
|
| Pelvic Pain | 4 | 2021 | 17 | 1.010 |
Why?
|
| Colitis | 1 | 2023 | 51 | 0.800 |
Why?
|
| Child | 23 | 2025 | 7229 | 0.780 |
Why?
|
| Constipation | 3 | 2025 | 37 | 0.750 |
Why?
|
| Hyperalgesia | 2 | 2018 | 41 | 0.710 |
Why?
|
| Chronic Pain | 3 | 2018 | 178 | 0.660 |
Why?
|
| TRPV Cation Channels | 1 | 2018 | 8 | 0.590 |
Why?
|
| Escherichia coli Infections | 2 | 2017 | 28 | 0.570 |
Why?
|
| Chemokine CCL2 | 1 | 2018 | 68 | 0.570 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2018 | 50 | 0.570 |
Why?
|
| Diet Therapy | 1 | 2016 | 8 | 0.500 |
Why?
|
| Muscarinic Antagonists | 1 | 2016 | 25 | 0.490 |
Why?
|
| Encopresis | 1 | 2015 | 5 | 0.490 |
Why?
|
| Telemedicine | 4 | 2023 | 493 | 0.480 |
Why?
|
| Central Nervous System Sensitization | 1 | 2014 | 1 | 0.440 |
Why?
|
| Esophagus | 2 | 2020 | 83 | 0.430 |
Why?
|
| Hepatolenticular Degeneration | 1 | 2013 | 6 | 0.420 |
Why?
|
| Spasm | 1 | 2013 | 9 | 0.420 |
Why?
|
| Muscle Cramp | 1 | 2013 | 5 | 0.420 |
Why?
|
| Irritable Bowel Syndrome | 3 | 2022 | 17 | 0.420 |
Why?
|
| Esophageal Spasm, Diffuse | 1 | 2013 | 1 | 0.410 |
Why?
|
| Muscle Weakness | 1 | 2013 | 45 | 0.410 |
Why?
|
| Hernia, Umbilical | 1 | 2013 | 22 | 0.410 |
Why?
|
| Humans | 29 | 2025 | 52593 | 0.410 |
Why?
|
| Escherichia coli | 1 | 2014 | 186 | 0.400 |
Why?
|
| Anal Canal | 2 | 2025 | 27 | 0.350 |
Why?
|
| Delivery of Health Care | 1 | 2013 | 324 | 0.330 |
Why?
|
| Adolescent | 11 | 2025 | 6737 | 0.330 |
Why?
|
| Carboxylic Ester Hydrolases | 2 | 2021 | 7 | 0.330 |
Why?
|
| Cystitis, Interstitial | 2 | 2021 | 10 | 0.320 |
Why?
|
| Child, Preschool | 7 | 2025 | 4062 | 0.310 |
Why?
|
| Female | 14 | 2025 | 28262 | 0.260 |
Why?
|
| Fecal Incontinence | 2 | 2025 | 15 | 0.250 |
Why?
|
| Neuromuscular Agents | 1 | 2025 | 8 | 0.240 |
Why?
|
| Botulinum Toxins, Type A | 1 | 2025 | 14 | 0.230 |
Why?
|
| Disease Models, Animal | 4 | 2021 | 1486 | 0.230 |
Why?
|
| Administration, Intravaginal | 1 | 2023 | 6 | 0.210 |
Why?
|
| Mesalamine | 1 | 2023 | 12 | 0.210 |
Why?
|
| Vagina | 1 | 2023 | 46 | 0.210 |
Why?
|
| Infant | 4 | 2017 | 3720 | 0.200 |
Why?
|
| Adult | 6 | 2024 | 14170 | 0.200 |
Why?
|
| Male | 12 | 2025 | 26863 | 0.200 |
Why?
|
| Mice, Inbred C57BL | 3 | 2018 | 1900 | 0.200 |
Why?
|
| Fellowships and Scholarships | 2 | 2020 | 127 | 0.190 |
Why?
|
| Duodenum | 2 | 2021 | 34 | 0.180 |
Why?
|
| Urinary Bladder | 2 | 2021 | 101 | 0.180 |
Why?
|
| Societies, Medical | 4 | 2025 | 202 | 0.180 |
Why?
|
| North America | 4 | 2023 | 77 | 0.180 |
Why?
|
| Diagnosis, Differential | 2 | 2015 | 1048 | 0.180 |
Why?
|
| Age Factors | 2 | 2015 | 1132 | 0.170 |
Why?
|
| Gastroparesis | 1 | 2019 | 10 | 0.160 |
Why?
|
| Manometry | 2 | 2025 | 22 | 0.160 |
Why?
|
| Healthcare Disparities | 1 | 2023 | 300 | 0.160 |
Why?
|
| Cohort Studies | 2 | 2013 | 1553 | 0.150 |
Why?
|
| Uropathogenic Escherichia coli | 1 | 2018 | 2 | 0.150 |
Why?
|
| Capsaicin | 1 | 2018 | 14 | 0.150 |
Why?
|
| Mice | 3 | 2021 | 5958 | 0.140 |
Why?
|
| Education, Medical, Graduate | 1 | 2020 | 220 | 0.140 |
Why?
|
| Pseudorabies | 1 | 2017 | 1 | 0.140 |
Why?
|
| Ganglia, Spinal | 1 | 2018 | 53 | 0.140 |
Why?
|
| Colorectal Neoplasms | 1 | 2021 | 295 | 0.140 |
Why?
|
| Nausea | 1 | 2017 | 46 | 0.140 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2017 | 76 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 178 | 0.130 |
Why?
|
| Eosinophilic Esophagitis | 1 | 2017 | 43 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 189 | 0.130 |
Why?
|
| Lipopolysaccharides | 1 | 2018 | 206 | 0.130 |
Why?
|
| Stomach | 1 | 2017 | 82 | 0.130 |
Why?
|
| Urinary Bladder, Overactive | 1 | 2016 | 5 | 0.130 |
Why?
|
| Dyspepsia | 1 | 2016 | 11 | 0.130 |
Why?
|
| Young Adult | 2 | 2023 | 4337 | 0.130 |
Why?
|
| Cyproheptadine | 1 | 2016 | 2 | 0.130 |
Why?
|
| Dicyclomine | 1 | 2016 | 3 | 0.130 |
Why?
|
| Gastroesophageal Reflux | 1 | 2016 | 48 | 0.130 |
Why?
|
| Amitriptyline | 1 | 2016 | 13 | 0.120 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2016 | 28 | 0.120 |
Why?
|
| Gastrointestinal Agents | 1 | 2016 | 41 | 0.120 |
Why?
|
| Pandemics | 1 | 2020 | 587 | 0.120 |
Why?
|
| Retrospective Studies | 5 | 2025 | 6671 | 0.120 |
Why?
|
| Animals | 4 | 2021 | 13507 | 0.120 |
Why?
|
| Comorbidity | 2 | 2016 | 631 | 0.110 |
Why?
|
| Internship and Residency | 1 | 2020 | 449 | 0.110 |
Why?
|
| Cephalosporins | 1 | 2015 | 37 | 0.110 |
Why?
|
| Quality of Life | 2 | 2021 | 882 | 0.110 |
Why?
|
| O Antigens | 1 | 2014 | 4 | 0.110 |
Why?
|
| Asymptomatic Infections | 1 | 2014 | 5 | 0.110 |
Why?
|
| Acute Pain | 1 | 2014 | 11 | 0.110 |
Why?
|
| Parents | 1 | 2017 | 332 | 0.110 |
Why?
|
| Esophageal Motility Disorders | 1 | 2013 | 2 | 0.100 |
Why?
|
| Gene Expression Regulation | 1 | 2018 | 1006 | 0.100 |
Why?
|
| Nifedipine | 1 | 2013 | 25 | 0.100 |
Why?
|
| Esophageal Achalasia | 1 | 2013 | 7 | 0.100 |
Why?
|
| Infant Behavior | 1 | 2013 | 18 | 0.100 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 2291 | 0.100 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2013 | 32 | 0.100 |
Why?
|
| Siblings | 1 | 2013 | 34 | 0.100 |
Why?
|
| Chest Pain | 1 | 2013 | 58 | 0.100 |
Why?
|
| Calcium Channel Blockers | 1 | 2013 | 60 | 0.100 |
Why?
|
| Recurrence | 1 | 2014 | 683 | 0.100 |
Why?
|
| Deglutition Disorders | 1 | 2013 | 79 | 0.090 |
Why?
|
| Feeding Behavior | 1 | 2013 | 192 | 0.090 |
Why?
|
| Signal Transduction | 1 | 2018 | 1714 | 0.090 |
Why?
|
| Case-Control Studies | 1 | 2013 | 1202 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2015 | 803 | 0.080 |
Why?
|
| Prevalence | 3 | 2017 | 1017 | 0.070 |
Why?
|
| Treatment Outcome | 3 | 2025 | 5486 | 0.070 |
Why?
|
| Clinical Competence | 2 | 2021 | 404 | 0.070 |
Why?
|
| Infant, Newborn | 1 | 2015 | 2891 | 0.070 |
Why?
|
| Risk Factors | 1 | 2015 | 3952 | 0.060 |
Why?
|
| Colombia | 2 | 2017 | 15 | 0.060 |
Why?
|
| Defecation | 1 | 2025 | 9 | 0.060 |
Why?
|
| Injections | 1 | 2025 | 61 | 0.060 |
Why?
|
| Migraine Disorders | 1 | 2025 | 47 | 0.060 |
Why?
|
| Evidence-Based Medicine | 1 | 2025 | 269 | 0.050 |
Why?
|
| Students | 2 | 2017 | 228 | 0.050 |
Why?
|
| Societies | 1 | 2023 | 8 | 0.050 |
Why?
|
| Enema | 1 | 2021 | 9 | 0.050 |
Why?
|
| Colostomy | 1 | 2021 | 11 | 0.050 |
Why?
|
| Poverty | 1 | 2023 | 219 | 0.040 |
Why?
|
| Pain Measurement | 1 | 2022 | 257 | 0.040 |
Why?
|
| Cell Count | 1 | 2021 | 144 | 0.040 |
Why?
|
| Mast Cells | 1 | 2021 | 55 | 0.040 |
Why?
|
| Eosinophils | 1 | 2021 | 44 | 0.040 |
Why?
|
| Competency-Based Education | 1 | 2020 | 29 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2022 | 718 | 0.040 |
Why?
|
| Gastrointestinal Motility | 1 | 2020 | 49 | 0.040 |
Why?
|
| Research Design | 1 | 2022 | 358 | 0.040 |
Why?
|
| Intestinal Mucosa | 1 | 2021 | 225 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2021 | 284 | 0.040 |
Why?
|
| Pain Perception | 1 | 2017 | 4 | 0.040 |
Why?
|
| Chicago | 1 | 2017 | 12 | 0.040 |
Why?
|
| Curriculum | 1 | 2021 | 399 | 0.030 |
Why?
|
| Pain Threshold | 1 | 2017 | 42 | 0.030 |
Why?
|
| Gastroenteritis | 1 | 2017 | 19 | 0.030 |
Why?
|
| Quantitative Trait Loci | 1 | 2017 | 50 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2017 | 310 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2017 | 187 | 0.030 |
Why?
|
| Inflammation | 1 | 2021 | 644 | 0.030 |
Why?
|
| Midwestern United States | 1 | 2016 | 26 | 0.030 |
Why?
|
| Behavior, Animal | 1 | 2017 | 187 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2017 | 176 | 0.030 |
Why?
|
| Schools | 1 | 2017 | 172 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 396 | 0.030 |
Why?
|
| Biopsy | 1 | 2017 | 607 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2017 | 910 | 0.030 |
Why?
|
| Phenotype | 1 | 2017 | 800 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 528 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 1037 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2013 | 138 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 1686 | 0.020 |
Why?
|
| United States | 1 | 2021 | 5227 | 0.020 |
Why?
|